DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below Fifty Day Moving Average – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.37 and traded as low as $2.99. DBV Technologies shares last traded at $3.09, with a volume of 24,330 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright lifted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a report on Tuesday, December 10th. Finally, StockNews.com initiated coverage on DBV Technologies in a report on Wednesday. They issued a “hold” rating on the stock.

DBV Technologies Stock Performance

The business has a 50-day simple moving average of $3.36 and a 200-day simple moving average of $3.87. The company has a market cap of $66.85 million, a price-to-earnings ratio of -0.72 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.